Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to -$4.8 million.

  • UroGen Pharma's Change in Accured Expenses fell 1769.48% to -$4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year increase of 1581.58%. This contributed to the annual value of $10.9 million for FY2024, which is 16216.61% up from last year.
  • As of Q3 2025, UroGen Pharma's Change in Accured Expenses stood at -$4.8 million, which was down 1769.48% from $7.1 million recorded in Q2 2025.
  • UroGen Pharma's 5-year Change in Accured Expenses high stood at $13.0 million for Q2 2024, and its period low was -$5.8 million during Q1 2024.
  • Moreover, its 5-year median value for Change in Accured Expenses was -$297000.0 (2021), whereas its average is $657526.3.
  • In the last 5 years, UroGen Pharma's Change in Accured Expenses tumbled by 42768.36% in 2023 and then surged by 189436.04% in 2024.
  • UroGen Pharma's Change in Accured Expenses (Quarter) stood at $472000.0 in 2021, then soared by 759.11% to $4.1 million in 2022, then crashed by 39.46% to $2.5 million in 2023, then surged by 215.52% to $7.7 million in 2024, then plummeted by 161.83% to -$4.8 million in 2025.
  • Its Change in Accured Expenses stands at -$4.8 million for Q3 2025, versus $7.1 million for Q2 2025 and -$3.6 million for Q1 2025.